Alvimopan (Alvimopan) Patent Expiration, LOE Window & CMS Spending

Alvimopan (Alvimopan) by Endo Pharmaceuticals: Multi-Source Generic Molecule, 3 AB generics, $47K 2024 CMS Part D & Medicaid spend, and $4,975 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEndo Pharmaceuticals
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$47K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$47K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,975 intro WAC)